Resumo

RICARDO, Amaru et al. HIGH ALTITUDE PATHOLOGICAL ERYTHROCYTOSIS: BIOLOGICAL CHARACTERIZATION, DIAGNOSIS AND TREATMENT. Rev. Méd. La Paz [online]. 2013, vol.19, n.2, pp.5-18. ISSN 1726-8958.

Introduction. The residents of high altitude get use to it in different ways, following the same purpose in order to supply oxygen and survival. In the present paper, we characterize the High Altitude Pathological Erythrocytosis disease and demonstrate the effectiveness of atorvastatin in its treatment. Material and methods. We studied male subjects as normal controls (CN), and patients with High Altitude Pathological Erythrocytosis (EPA), Secondary Erythrocytosis (ES) and Polycythemia Vera (PV). Laboratory and molecular biology studies were conducted. We developed in the study of 2nd phase with atorvastatin. Results. The EPA presents: normal erythropoietin, delayed erythroid progenitors apoptosis, autonomous growth of BFU-E and hypersensitivity to erythropoietin. The atorvastatin in patient with EPA, decreased hemoglobin concentration and eliminates the symptomatology of blood hyperviscosity Conclusions. The EPA has characteristics that distinguish it from other pathologic erythrocytosis and atorvastatin becomes an effective treatment.

Palavras-chave : High Altitude Pathological Erythrocytosis; Chronic Mountain Sickness; Statins.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )